Prostate Cancer
Telix Pharmaceuticals Begins Phase III Radiopharmaceutical Trial in PSMA-Positive mCRPC
The firm believes TLX591 could have advantages over other PSMA-directed radiopharmaceuticals thanks to its shorter, two-dose treatment course.
Pluvicto monotherapy recently benefitted a similar prostate cancer population in another trial, but researchers anticipate efficacy and safety advantages with the immunotherapy combination.
Merck KGaA, Hengrui Pharmaceuticals Ink Oncology Drug Licensing Deal Potentially Worth $1.48B
Merck KGaA gained exclusive rights to Hengrui's PARP inhibitor HRS-1167 and an option for exclusive rights to its CLDN18.2 antibody-drug conjugate SHR-A1904.
Novartis Focused on Radiopharmaceutical Expansion After Pluvicto, Lutathera Sales Both Grow in Q3
Premium
The Swiss drugmaker also reported revenue increases across other precision oncology products including its breast cancer drug Kisqali.
Pluvicto Delays Progression in Earlier mCRPC, but Crossover Muddies Overall Survival Analysis
Premium
Metastatic prostate cancer patients who received prior hormone therapy benefited from Novartis' PSMA-targeted radiopharmaceutical in the PSMAfore trial.